The first participant in the Tumaini vaccine trial was vaccinated in Bunia, Democratic Republic of the Congo, on 23 October 2026. The trial begins with Ervebo, an existing Ebola vaccine, but asks a question its current licence cannot answer: whether it can protect against Bundibugyo virus, the cause of the ongoing outbreak. Trial launch announcement
There is no approved vaccine against Bundibugyo, according to the announcement from CEPI and the trial partners. Vaccinating a first participant starts the process of gathering evidence; it does not establish that the candidate works against this virus.
The virus name changes the evidence question
“Ebola” can obscure an important distinction. Ervebo is licensed to prevent disease caused by Ebola virus, historically known as Zaire ebolavirus. Bundibugyo is a different virus. Evidence supporting an authorised use against one cannot simply be transferred to the other.
WHO’s candidate-prioritisation group examined the possibility of cross-protection in July. Its public meeting overview describes evidence including animal challenge and laboratory findings. The group recommended prioritising Ervebo in an outbreak research study while leaving open the later addition of a Bundibugyo-specific candidate. That was a recommendation to generate evidence in people, rather than a declaration that human protection against Bundibugyo had been demonstrated. WHO prioritisation overview
This distinction explains why an established vaccine can enter a new trial. The product is familiar, but the proposed protective use still needs investigation.
One trial framework can assess more than one candidate
Tumaini is described as an adaptive Phase 2/3 platform trial. The framework is intended to evaluate the safety, immune response and efficacy of vaccine candidates within a shared programme. Ervebo is the first candidate; preparations are under way for Bundibugyo-specific candidates being developed by Moderna and by the University of Oxford with Serum Institute of India to join later. Their anticipated inclusion is a plan, not evidence that they have already entered this trial or produced results. CEPI and partner announcement
The announcement describes ring vaccination focused on contacts at high risk of infection. This places research around people connected to cases during the response. It is different from offering a proven vaccine routinely to everyone in an affected country.
The value of the platform is organisational as well as scientific: candidates can be assessed within an existing trial framework as they become ready. The framework still has to produce findings about the candidates themselves. A common programme does not make different vaccines interchangeable.
The outbreak response and the trial have different responsibilities
The Institut National de Recherche Biomédicale and the University of Antwerp co-lead and co-sponsor Tumaini, under national leadership from the DRC Ministry of Health. CEPI supplies funding and scientific and operational support. WHO and other partners support the work alongside the wider response. These are stated roles in a collaborative trial, rather than separate independent demonstrations of vaccine effectiveness. Trial leadership and funding
The broader outbreak requires surveillance, investigation and care while the research proceeds. ECDC’s outbreak overview separately records the outbreak’s geography and its evolving public-health assessment. Those updates serve a different task from a vaccine trial report, and their dates should be retained rather than combined into an apparently same-day trial result. ECDC outbreak overview
Community participation is also part of trial delivery. The launch describes work with affected communities and national authorities; it does not supply a measured result showing that every community has accepted the study or that its implementation problems have been resolved.
What would change the story next
The important next evidence is a trial update that defines who was studied, which candidate and comparison were used, the outcomes assessed, follow-up, uncertainty and reported harms. An immune response, protection from disease and an effect on severe outcomes are related research questions, but they are not interchangeable results.
For now, the milestone is specific: an outbreak trial has begun to test a protection gap that an existing Ebola vaccine licence leaves open. No vaccine-effectiveness result or personal vaccination recommendation follows from that first administration.